Format

Send to

Choose Destination
APMIS. 2017 Dec;125(12):1063-1069. doi: 10.1111/apm.12749. Epub 2017 Sep 8.

A role of human beta defensin-1 in predicting prostatic adenocarcinoma in cases of false-negative biopsy.

Author information

1
Department of Pathology, Soonchunhyang University Cheonan Hospital, Cheonan, Korea.
2
Department of Urology, Soonchunhyang University Cheonan Hospital, Cheonan, Korea.
3
Department of Pathology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.
4
Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.

Abstract

The purpose of this study was to clarify the role of human beta defensin-1 (hBD-1) in predicting PAC in morphologically normal prostate glands. In total, 25 patients with a negative initial biopsy for PAC and diagnosed as PAC positive in subsequent biopsies performed within 1 year of the initial biopsy were included. As a control group, 22 patients negative for PAC in at least three consecutive histologic examinations were selected. Expression of hBD-1 was analyzed separately via immunohistochemistry in paired cores of non-neoplastic gland and PAC in the false-negative group and control group. Loss of hBD-1 expression was observed in 95.6% and 90.0% PAC cases with Gleason Patterns 3 and 4 in repeat biopsies, respectively. hBD-1 loss of basal cells in 40 (85.1%) previous non-neoplastic biopsy cores in the false-negative group was observed, in contrast to preserved basal cell expression of hBD-1 in 64 (72.7%) biopsy cores in the control group (p = 0.001). Multivariate logistic regression analysis showed that hBD-1 basal cell loss (≥20% of prostatic glands in total cores) is an independent factor for predicting PAC (odds ratio: 4.739, confidence interval: 1.093-20.554, p = 0.038). hBD-1 loss of basal cells is a useful indicator to identify extremely high-risk patients with initially negative biopsy.

KEYWORDS:

Human beta defensin-1; false negative; immunohistochemistry; prostate adenocarcinoma; repeat biopsy

PMID:
28885732
DOI:
10.1111/apm.12749
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center